A frequent functional toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression
Oh, Djin-Yea,*; Baumann, Konstantina; Hamouda, Osamahb; Eckert, Jana Ka; Neumann, Konradc; Kücherer, Claudiab; Bartmeyer, Barbarab; Poggensee, Gabrieleb; Oh, Naria,d; Pruss, Axele; Jessen, Heikod; Schumann, Ralf Ra
aInstitute for Microbiology and Hygiene, Charité University Medical Center, Germany
bRobert Koch Institute, Germany
cDepartment of Medical Biometry and Clinical Epidemiology, Charité University Medical Center, Germany
dThe Berlin Trial on HIV and TLR SNPs, Gemeinschaftspraxis Jessen-Jessen-Stein, Germany
eInstitute of Transfusion Medicine, Charité University Medical Center, Berlin, Germany.
* Present address: The Floating Hospital for Children, Tufts Medical Center, Boston, Massachusetts, USA.
Received 22 August, 2008
Revised 8 October, 2008
Accepted 14 October, 2008
Correspondence to Ralf R. Schumann, MD, PhD, Institute for Microbiology and Hygiene, Charité-Universitätsmedizin Berlin, Dorotheenstr. 96, 10117 Berlin, Germany. Tel: +49 30 450 524141; fax: +49 30 450 524941; e-mail: firstname.lastname@example.org
Objectives: Toll-like receptors (TLRs) play an important role in the innate immune response to pathogens. TLR7 recognizes RNA of various viruses including HIV. The objective of this study was to examine the influence of individual genetic variations of TLR7 on the susceptibility to and progression of HIV disease.
Method: We genotyped a population of 734 HIV-positive adults and 545 healthy controls for three TLR7 single nucleotide polymorphisms. The frequency of TLR7 genetic variations was assessed and related to HIV disease progression. Furthermore, we analyzed peripheral blood mononuclear cells obtained from healthy individuals differing in their TLR7 genotype and assessed their response to a TLR7-specific ligand ex vivo.
Results: Presence of the most frequent TLR7 polymorphism, TLR7 Gln11Leu, was associated with higher viral loads and accelerated progression to advanced immune suppression in HIV patients. Furthermore, in women this polymorphism may be associated with increased HIV-1 susceptibility as it was found more frequently among patients as compared with controls. Peripheral blood mononuclear cells from polymorphism carriers secreted significantly less IFN-α following TLR7 activation, whereas IL-6 production remained unaltered.
Conclusion: This is the first report of a functional TLR7 variant to be associated with susceptibility to and a more severe clinical course of HIV-1 disease. These results may have implications for the risk assessment of individual patients as well as for HIV-1 therapy and vaccination strategies in the future.
Toll-like receptors (TLRs) are pattern recognition receptors (PRRs) playing a key role in innate immune defense against a wide diversity of pathogens [1,2]. TLR-mediated recognition of highly conserved so-called ‘pathogen-associated molecular patterns (PAMPs)’ initiates complex signaling cascades, culminating in the activation of transcription factors such as nuclear factor (NF)κB and interferon regulatory factor (IRF)-7 [3,4]. The resulting differential gene expression, which varies depending on which TLR has been activated, leads to potent innate immune responses against the pathogen and modifies the adaptive immune response.
Ten human TLRs have been identified . Although TLR research initially concentrated on bacterial PAMPs, it is now firmly established that viruses also interact with the TLR system . TLRs implicated in the response to viral stimulation include TLR7 and TLR8 sensing viral single-strand RNA [7–9]. The outcome of viral TLR activation exhibits wide individual variation ranging from effective antiviral response to viral replication and spread .
Individual variation of the host response is particularly important for HIV. HIV-1 RNA activates TLR7/8 [8,11,12]. For both, TLR7 stimulation and TLR8 stimulation, an anti-HIV effect has been demonstrated depending on an enhancement of the adaptive [13,14], and also the innate immune response [15,16]. In acute HIV-infection, TLR8-induced HIV-restriction depends on unknown soluble factors , whereas TLR7-induced HIV-constraint is governed mainly by IFNα . HIV-1 RNA induces the release of IFNα in plasmacytoid dendritic cells (pDCs) via TLR7 activation ; type I interferons induce a wide range of antiretroviral factors and potently restrict HIV-1 replication in vitro [17–23] and in vivo [24–26].
Conversely, TLR ligands have been demonstrated to mediate a continuous activation of the immune system driving viral replication and progression to AIDS [27–29]. As the HIV-long terminal repeat (LTR) contains NFκB transcription sites, TLR-triggered NFκB activation leading to LTR-dependent transcription is viewed as one of the mechanisms for increased HIV-1 replication [15,27,29–31]. Furthermore, immune activation has been implicated with natural killer (NK)-cell activation in viremic HIV infection and is regarded as a hallmark of chronic HIV-1 disease . Recent evidence suggests that HIV itself contributes substantially to this process by TLR7/8 ligation of viral RNA [12,33,34]. The progression of HIV disease might therefore depend on the complex balance of TLR7/8-mediated-immune activation, a mechanism favorable to the virus, and TLR7/8-mediated induction of IFNα and other soluble factors, a mechanism favorable to the host.
TLR7 employs the adaptor molecule MyD88 for the induction of both IFNα and inflammatory responses. Downstream, the signaling pathway splits: IFNα is induced through the activation of IRF7, whereas inflammatory cytokines such as IL-6 are induced through activation of NF-κB. The IRF7/IFN and the NF-κB/IL6 pathway have common as well as distinctive signaling mediators [35–38]. In certain experimental settings, it has been shown that the signaling threshold of the TLR axis is higher for IFNα induction than for NF-κB-dependent interleukin induction .
The importance of TLR7/8-mediated innate immune responses for HIV-1 disease outcome has become increasingly evident during the last years. The use of TLR7/8-specific agonists and antagonists is discussed as a novel approach for HIV-1 treatment [15,32,33]. Genetic variants of TLRs and downstream signaling molecules can influence the ability of the affected individual to respond to TLR ligands resulting in an altered susceptibility to or course of infectious disease [40–42]. Regarding HIV, it is established that variations within the host's genome contribute to the risk for acquiring infection as well as the individual rate of disease progression [43–48].
However, data on the relation between HIV-1 infections and TLR 7/8 single nucleotide polymorphisms (SNPs) are scarce and there is currently a lack of studies on the functional effects of TLR7/8 genetic polymorphisms . We were recently able to show that a common TLR8 mutation restricts HIV-1 disease progression, possibly by decreasing NFκB activation , and that the course of another RNA viral disease, hepatitis C virus (HCV) infection, correlates with the presence of certain TLR7 genotypes . We hypothesized that genetic variations of TLR7 might be functionally relevant and influence the progression of HIV disease. Here we show that a common TLR7 genetic variant restricting IFNα but not inflammatory responses is associated with higher viral loads as well as accelerated disease progression in HIV-1-infected individuals. This is the first functional study of a TLR7 genetic variant affecting the progression of HIV-1 disease.
Material and methods
Three coding nonsynonymous TLR7 SNPs were determined in the study group by real-time PCR assays. Of these, two (Gln11Leu, Ala448Val) are coding nonsynonymous SNPs reported at an allelic frequency of more than 1% in the Entrez dB SNP database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp and http://www.ensembl.org/); the third (T-120G) was previously identified to be related to another RNA-viral disease, HCV infection . Whereas Gln11Leu and Ala448Val are located to exon 3 of the TLR7 gene, T-120G is an intronic polymorphism. The detailed PCR curve and melting curve analysis methodology is available online in the Supplementary Methods section.
The study group comprised a total of 1279 individuals of either White or African ethnicity, 734 HIV-1-positive adults [men 671 (91%); women 63 (9%); Whites 708 (96.5%); Africans 26 (3.5%); median age, 39 years (interquartile range, IQR, 34–43 years)], and 545 seronegative controls [men 489 (90%); women 56 (10%); Whites 510 (94%); Africans 35 (6%); median age 38 years (IQR 30–43 years)].
Seropositive individuals are HIV-1 patients either enrolled in the German HIV-1 Seroconverter Study (n = 646) or in the Berlin Trial on HIV and TLR SNPs (n = 88). The German HIV-1 Seroconverter Study is a nationwide study based on a cohort of HIV-infected individuals for whom the date of seroconversion can be reliably estimated as the midpoint between the last negative and the first positive HIV-1 antibody test within a maximum interval of 3 years, or the date of the first reactive test if acute seroconversion was documented [52–54]. The Berlin Trial on HIV and TLR SNPs was established for the purpose of this study and enrolled seroconverters (n = 24) and seroprevalent patients (n = 64) for whom the date of seroconversion has not been documented. Further details on both study cohorts are provided online in the Supplementary Methods section. For disease progression analyses, set point viral loads (available for 302 HIV-1 infected individuals; see Statistical Methods for definition) and, in Kaplan–Meier analysis of 464 seroconverters, the time from seroconversion to advanced immunosuppression as defined by a CD4+ T-cell count less than 350 μl were assessed. To preclude confounding effects, CD4+ T-cell count and viral load values gathered before the start of any antiretroviral treatment were considered only. Furthermore, carriers of the established HIV-protective CCR5Δ32 deletion [43,55–60] were excluded in a second step of both viral load and survival analysis.
The HIV-negative control collective consisted of 425 anonymized seronegative White blood donors and 120 healthy, unrelated volunteers. This group has been previously described ; for the survey reported here, 53 individuals (48 cases, five controls) were excluded from analysis, either because TLR7 genotyping was not feasible or because they were of rare or unknown ethnicity. Informed consent has been obtained, and written approval from the relevant ethical boards has been granted for all studied participants.
Genotype frequencies of seropositive and seronegative individuals were compared using χ2 tests. Viral set points, defined as the median of all values of log10-transformed copies of HIV-1 RNA measured in plasma between 100 days and 2 years postseroconversion [47,61], were available for 302 therapy-naive patients. To evaluate the correlation between TLR7 genotypes and viral load, individual set points in each genetic group were compared by the nonparametric Mann–Whitney test. Survival analysis was conducted using the Kaplan–Meier method with an endpoint of less than 350 CD4+ T cells/μl. Differences between genotypes were analyzed by the log-rank test. P values less than 0.05 were considered statistically significant. We used SPSS14.01 software (SPSS Inc., Chicago, Illinois, USA) for data management and statistical analyses, and PRISM 4 for figures.
Isolation and stimulation of peripheral blood mononuclear cells
Whole blood was obtained from age-matched pairs of healthy volunteers differing in their TLR7Gln11Leu genotype. All donors were healthy White males negative for the TLR7 T-120G, TLR7 Ala448Val and TIRAP Ser180Leu polymorphisms who had given written informed consent before donation. Detailed protocols for isolation and cultivation of peripheral blood mononuclear cells (PBMCs) are provided online in the Supplementary Methods section.
After seeding, cells were stimulated with 100 μl supplemented medium per well containing the respective ligands Imiquimod (Invivogen, Toulouse, France) and lipopolysaccharide (LPS) (Re595; Sigma, Deisenhofen, Germany) at the indicated concentrations. IFNα and IL-6 protein levels were measured from cell culture supernatants in a sandwich enzyme-linked immunosorbent assay (ELISA) procedure, which is supplied in detail in the Supplementary Methods section.
To test the hypothesis that TLR7 genetic variation is related to the risk for, or the course of HIV-1 infection, distribution of three polymorphisms was analyzed in a total study population of 1279 participants. Of these, 734 were HIV-1 positive individuals and 545 were seronegative controls, matched according to age, ethnicity and sex.
Distribution of toll-like receptor 7 mutant alleles in HIV-1 patients and controls
If presence of a certain gene variant modifies the susceptibility to HIV-1, its frequency should vary between seropositive and seronegative populations. Thus, we compared TLR7 polymorphism frequencies for HIV-1-infected patients and controls. Because of the X-chromosomal localization of the TLR7 gene, analyses were conducted separately according to sex (Table 1).
The TLR7 T-120G polymorphism was found in White participants only and was absent in Africans. In White males, the proportion of hemizygotes ranged between 4.9% in seronegatives and 5.8% in seropositives; this difference was not significant. In women, the frequency of heterozygotes among HIV patients (12.7%) was similar as observed for healthy controls (10.7%).
The TLR7 Ala448Val alteration was found to be rare, with a total of eight SNP carriers detected in the entire study collective. All of these were White males. Two of them were HIV-infected, whereas the other six hemizygotes belonged to the seronegative control group corresponding to proportions of 0.3 and 1.3%, respectively.
Regardless of serostatus, ethnicity, and sex TLR7 Gln11Leu represented the single most common genetic variation in all subgroups examined. In men, frequencies of hemizygotes were roughly similar in HIV-patients (23.4%) and in HIV-negative controls (20.9%; P = 0.305). By contrast, in HIV-infected women the mutant allele carriage frequency was significantly higher than that observed in healthy controls (P = 0.002). This distinction remained significant when analysis was restricted to women of either White or African ethnic background. The association might represent a stochastic event, given the low number of women in our study collective. However, it may also indicate that female carriers of the TLR7 Gln11Leu variant allele are at an increased risk of being infected with HIV-1.
Association of toll-like receptor 7 polymorphisms with HIV-1 disease progression
We next examined whether either of the two common TLR7 SNPs examined here, TLR7 T-120G and TLR7 Gln11Leu, were related to the severity of HIV-1 disease. To this end, we first analyzed baseline CD4+ T-cell counts and observed lower CD4+ T-cell counts in male TLR7 Gln11Leu mutation carriers as compared with carriers of the common allele (Supplementary Table S1). To assess the influence of these polymorphisms on disease progression, we examined their association with set point viral loads and with the endpoint of less than 350 CD4+ T cells/μl, which signifies immunologically advanced HIV-1 infection. Because of the low number of women with these parameters available, analysis was confined to male seropositives.
Impact of toll-like receptor 7 genotype on HIV-1 set point viral load
We observed no association between TLR7 T-120G genotype and set point plasma viral loads (see Material and Methods for a definition), implying that this polymorphism does not play a role in establishing steady-state levels of HIV-1 after seroconversion (Table 1).
Regarding TLR7 Gln11Leu genotype, however, males hemizygous for the rare ‘Leu’ alteration displayed significantly higher set point viral loads implying a deleterious effect of the minor gene variant (P = 0.017; Fig. 1a). To exclude confounding issues resulting from different ethnic backgrounds, the analysis was limited to Whites and this difference remained significant (P = 0.013; data not shown). When individuals heterozygous for the HIV-1 protective CCR5Δ32 deletion were excluded from analysis, the distinction between genotypes was more pronounced (P = 0.006; Fig. 1b).
Relation between toll-like receptor 7 genotype and advanced immunological stage of HIV-1 infection
A CD4+ T-cell count less than 350/μl is the immunological criterion for advanced HIV-1 disease in adults; it firmly indicates the need to initiate antiretroviral therapy according to the revised European  and American  guidelines. We hypothesize that the time until the CD4+ T-cell number reaches 350/μl depends on TLR7 genetic variation.
Although no such association was observed for the TLR7 T-120G SNP (data not shown), Kaplan–Meier analysis of 464 seroconverters revealed that TLR7 Gln11Leu hemizygotes took a median time of 17 [95% confidence interval (CI): 12–22] months to reach the study endpoint of less than 350 CD4+ T cells/μl, whereas carriers of the normal gene variant took a median 32 [24–40] months, indicating an accelerated disease course in Gln11Leu mutation carriers. This difference was significant (P = 0.021; Fig. 2a), remained so when only Whites were considered (P = 0.020; data not shown), and was more pronounced in the subgroup of individuals negative for the CCR5Δ32 deletion (P = 0.011; Fig. 2b).
We conclude that presence of the TLR7 Gln11Leu genetic variation is associated with a detrimental effect on HIV-1 disease progression as defined by viral set points and the time in reaching a stage of immunologically advanced infection. This prompted us to study the functional impact of the Gln11Leu polymorphism by use of ex-vivo cell stimulation assays.
Effect of the Gln11Leu polymorphism on toll-like receptor 7 stimulation ex vivo
This SNP is common in White populations providing a chance to examine its functional relevance ex vivo. We obtained PBMCs from healthy volunteers that had been genotyped for the TLR7 SNPs, stimulated the cells employing the TLR7-specific ligand Imiquimod and measured IFNα as well as IL-6 secretion in the supernatants. Donors hemizygous for the rare ‘Leu’-allele were compared with matched donors hemizygous for the common ‘Gln’ variant.
Following Imiquimod treatment at 5 μmol/l, a time-dependent IFNα response was observed which was lower in ‘Leu’ hemizygotes than in ‘Gln’ hemizygotes (P = 0.05). Regarding IL-6 response, the difference was weak and did not reach statistical significance (Fig. 3a). Next, we assessed dose-response relationships following 8 and 24 h of Imiquimod treatment. Again, presence of the ‘Leu’ allele was associated with decreased IFNα levels, whereas IL-6 levels were similar in donors of both genotypes (Fig. 3b,c). After normalization according to LPS-induced IL-6 levels, a TLR7-independent measure of cell activation, significance levels did not change (data not shown). These findings imply that TLR7 activation leads to a weakened IFNα response in TLR7 Gln11Leu SNP carriers as compared with wild type controls.
Of interest, the shapes of IFNα and IL-6 dose-response curves differed. Depending on TLR7 genotype and incubation time, maximum IFNα concentrations were induced by Imiquimod-doses between 5 and 10 μmol/l, whereas higher doses led to diminished IFNα levels; a cytopathic effect of the higher Imiquimod doses seems unlikely because for IL-6, at doses up to 100 μmol/l, a steadily increasing response was observed.
TLRs are of crucial importance for the detection of viruses and the subsequent elicitation of an antiviral response . Clearance of a variety of viral infections, for example, vesicular stomatitis virus, cytomegalovirus and hepatitis B virus is critically dependent on TLR activation [64–66].
TLR7/8 stimulation has been demonstrated to confer anti-HIV activity in vivo [13,14] and ex vivo [15,16]. On the other hand, TLR7/8 triggering has recently been implicated with persistent immune activation, a hallmark of progressive HIV-1 infection [32–34]. It therefore has been suggested by others that modulation of TLR7/8 signaling may represent a novel concept for future antiviral therapy [32–34]. We have recently identified a functional TLR8 variant associated with a restriction of HIV-1 disease  and in the present study present evidence for the association of a functional TLR7 variant with HIV-1 disease progression.
We detected a robust relationship between the TLR7 ‘Leu’ genetic variant and higher set point viral loads. Progression to an advanced stage of immune suppression was accelerated in TLR7 ‘Leu’ carriers. We observed that presence of the TLR7Gln11Leu SNP was associated with lower baseline CD4+ T-cell counts and possibly increased HIV-1 susceptibility in women; these results are suggestive of a strong effect on the initial stages of HIV infection. Assuming that the deleterious effect of the TLR7 Gln11Leu genetic alteration depends on a diminished IFNα induction, these findings would be in line with the fact that IFNα production is of importance for the control of HIV replication during early, rather than late disease stages [24–26].
We observed an overrepresentation of the rare TLR7Gln11Leu genetic variant in HIV-1 infected females as compared with HIV-negative controls implying an increased risk for HIV-1 acquisition. This association was found in female but not male study participants; possible explanations may involve the significant gender-specific variation of IFNα levels induced by TLR7 ligands . The number of women included in our study is less and the observed effect may well be due to a stochastic event only. Thus, confirmatory studies involving higher numbers of female participants are needed; however, in a cohort of female patients with chronic HCV infection, a significantly increased frequency of this SNP was also reported . Taken together with these findings, our results suggest that, in vivo, presence of the TLR7 ‘Leu’ variant is associated with a gender-dependent increase of susceptibility not only to one but to various RNA viral diseases.
In our stimulation assays, the presence of the TLR7Gln11Leu variant was associated with decreased IFNα production. The induction of IL-6 was only marginally impaired. Although these data do not allow for direct conclusions on how this SNP exacerbates the course of HIV-1 disease, they suggest a selective impairment of the IRF7-dependent signaling pathway in TLR7Gln11Leu variant carriers. As a consequence, these individuals might suffer from a restriction of the antiretroviral IFNα response, leading to higher viral loads and accelerated disease progression. Moreover, the NFκB-dependent pathway culminating in the secretion of proinflammatory cytokines appears to remain unaltered. Thus, the mutant TLR7 protein would still be able to recognize HIV-1 RNA and contribute to chronic activation of the immune system, which is of major importance in AIDS pathogenesis [27,33]. pDCs are of paramount importance in linking innate and adaptive immunity to HIV and many other viruses. They are also the PBMC sub-population responsible for the bulk of IFNα production following TLR7 stimulation . Further studies are needed and currently underway in our laboratory to examine the effect of the Gln11Leu SNP on the IFNα and inflammatory cytokine response in pDCs.
At this point, we can only speculate about the molecular mechanism underlying the effect of the TLR7 Gln11Leu SNP on cytokine and interferon responses; possible explanations for its relevance include linkage disequilibrium with another genetic variation accounting for functional implications. However, this SNP is located in the signal sequence of TLR7, adjacent to the typical basic residues in the N-terminal part of this sequence. Signal peptide degeneracy, even when subtle, is known to modulate posttranslational modification, localization, quantity and thus the functionality of the affected protein . The IRF-7 dependent pathway is characterized by a higher signaling threshold than the NF-κB dependent pathway . Thus, lower quantities or impaired functionality of the variant TLR7 protein would indeed disturb IFNα rather than interleukin production.
The substantial impact of the host's genetic variation on the individual course of HIV-1 infection has been established during the last years and is subject of ongoing major studies [43,47,70,71]. The important role of TLRs, in particular TLR7, in HIV pathogenesis is currently being elucidated [11,12,15,16,34]. The data presented here demonstrates for the first time that TLR7 genetic variability influences HIV-1 progression. The whole genome association studies  that are currently underway will be needed to assess the relative contribution of genetic variation of this and other TLRs to the total genetic impact.
In summary, our results demonstrate the effect of a TLR7 genetic polymorphism on HIV disease progression in a German seroconverter cohort. Furthermore, presence of this polymorphism might lead to a gender-specific increase of the risk to acquire HIV-1. In TLR7-specific stimulation assays, we show ex vivo that presence of this mutation is associated with decreased production of IFNα but normal production of IL-6. This combination of limited antiretroviral IFNα activity with an unaltered degree of immune activation is a potential underlying mechanism for the exacerbated disease course in SNP carriers. The data presented here may help define an individual patient's HIV-1 risk profile. They are of interest with regard to the potential of TLR7 agonists and antagonists as immunomodulatory antiretroviral drugs.
We gratefully acknowledge the patients, their families and the clinicians whose participation in the German HIV-1 Seroconverter Study and in the Berlin Trial on HIV and TLR SNPs made these investigations possible. We thank Fränzi Creutzburg and Diana Woellner, Charité, Berlin, for outstanding technical support; Sabrina Neumann and Hanno von Spreckelsen for skillful technical assistance in preparation and asservation of DNA samples of seroconverters (German Seroconverter Study); TIBMolBiol/Genexpress for probe design and excellent genotyping support; Wolfgang Hoehne for the critical reading of the manuscript; Ulrike Schulz of MediMath for helpful discussions; and Martin Meixner of Cyano Biotech for outstanding help on sequence analysis. Carmen Zedlack (Gemeinschaftspraxis Jessen-Jessen-Stein, Berlin), Christian Kollan and Parvin Ghassim (Robert Koch-Institut, Berlin) provided invaluable data management support. This work forms part of the doctoral thesis of K.B. D.-Y.O. is a recipient of a Rahel Hirsch Grant of the Charité-Universitätsmedizin Berlin. R.R.S. was supported by grants obtained from the Deutsche Forschungsgemeinschaft (DFG). All authors state that they do not have any conflict of interest.
D.-Y.O. performed TLR7 genotyping, data analysis, recruitment of PBMC donors, obtained the ethical vote for PBMC stimulation experiments, and wrote the manuscript; K.B. performed TLR7 genotyping, data analysis, and PBMC stimulation assays; O.H. designed, supervised and conducted the German HIV-1 Seroconverter Study; J.K.E. performed PBMC stimulation assays; C.K., B.B. and G.P. provided DNA samples of the German HIV-1 Seroconverter Study patients, collected patient's data, and obtained the ethical vote for this collective; K.N. performed statistical analysis; H.J. and N.O. recruited patients of the Berlin Trial on HIV and TLR SNPs, provided EDTA blood samples and clinical data of these patients, and obtained the ethical vote of the Berlin Medical Association for this collective; A.P. recruited healthy controls; R.R.S. designed and supervised the project, and wrote the manuscript.
Aachen: Dres. Habets and Knechten; Augsburg: Dr Hammond (Klinikum Augsburg); Berlin: Dres. Mayr, Schmidt, Speidel, and Strohbach (Medizinisches Versorgungszentrum, Ärzteforum Seestraße), PD Dr Arasteh (Auguste-Viktoria-Krankenhaus/Vivantes), Dres. Bieniek and Cordes, Dr Claus, Dres. Baumgarten, Carganico, and Dupke, Dres. Freiwald and Rausch, Dres. Gölz, Klausen, Moll, and Schleehauf, Dr Hintsche, Dres. Jessen and Jessen, Dres. Köppe and Krauthausen, Dr Reuter; Bielefeld: Dr Pfaff (Krankenhaus MARA II); Bochum: Professor Dr Brockmeyer (St. Joseph-Hospital); Bonn: Professor Dr Rockstroh (Universitätsklinik Bonn); Dortmund: Professor Dr Gehring and Dr Schmalöer (Klinikum Dortmund, ID-Ambulanz); Dresden: Dr Sawatzki (Städtisches Krankenhaus Dresden-Neus); Duisburg: Dr Becker-Boost, Dr Kwirant; Düsseldorf: Professor Dr Häussinger and Dr Oette (Universitätsklinik Düsseldorf); Frankfurt/Main: Professor Dr Helm (Universitätsklinik Johann-Wolfgang-Goethe-Universität); Frankfurt/Oder: Dr Markus; Halle/Saale: Dr Kreft (Universitätsklinik Martin-Luther-Universität); Hamburg: Professor Dr Plettenberg, Dr Stoehr, Dr Graefe, and Dr Lorenzen (ifi, Allgemeines Krankenhaus St. Georg), Professor Dr Burchard, Dr Lippert, and Dr Manegold (Bernhard-Nocht-Institut); Dres. Adam, Schewe, and Weitner, Dr Fenske, Dr Gellermann, Professor Dr Stellbrink (Universitätsklinik Eppendorf); Hannover: Professor Dr Schmidt (Medizinische Hochschule Hannover), Dres. Buck and Leugner; Koblenz: Professor Dr Eisenhauer and Dr Rieke (Krankenhaus Kemperhof); Köln: Dr Bihari, Dr Ferdinand, Professor Dr Fätkenheuer (Universitätsklinik Köln); Leipzig: Dr Pfeil (Universitätsklinik Leipzig); Magdeburg: Professor Dr Malfertheiner and Dr Wolle (Universitätsklinik Otto-v.-Guericke-Universität); Mainz: Professor Dr Galle (Klinikum der Joh.-Gutenberg-Universität); München: Dres. Jäger and Jägel-Guedes, Dr Malm, Dr Rieger, Städtisches Krankenhaus München-Schwabing, Professor Dr Fröschl (Technische Universität München); Münster: Professor Dr Rahn, (Universitätsklinik Münster); Norderstedt: Dr Soldan; Nürnberg: Dr Brockhaus (Klinikum Nürnberg); Osnabrück: Dr Mutz (Städtische Klinik Natruper Holz); Regensburg: Professor Dr Salzberger, Professor Dr Schölmerich, and Dr Schneidewind (Universitätsklinik Regensburg); Remscheid: Dr Steege; Rostock: Dr Kreft, Professor Dr Ziegler and Professor Dr Reisinger (Universitätsklinik Rostock); Stuttgart: Dres. Ißler, Schaffert, Schnaitmann, and Trein, Dres. Frietsch, Müller, and Ulmer; Dr Wagner-Wiening (Landesgesundheitsamt Stuttgart); Ulm: Professor Dr Kern and Professor Dr Kreidler (Universitätsklinik Ulm); Viernheim: Dr van Treek; Wiesbaden: Dr Starke.
1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783–801.
2. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20:197–216.
3. Beutler B, Hoebe K, Du X, Ulevitch RJ. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol 2003; 74:479–485.
4. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006; 311:1–16.
5. Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, et al. Genetic analysis of host resistance: toll-like receptor signaling and immunity at large. Annu Rev Immunol 2006; 24:353–389.
6. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006; 7:131–137.
7. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529–1531.
8. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526–1529.
9. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 2004; 101:5598–5603.
10. Rassa JC, Ross SR. Viruses and toll-like receptors. Microbes Infect 2003; 5:961–968.
11. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via toll-like receptor-viral RNA interactions. J Clin Invest 2005; 115:3265–3275.
12. Meier A, Alter G, Frahm N, Sidhu H, Li B, Bagchi A, et al. MyD88-dependent immune activation mediated by HIV-1-encoded TLR ligands. J Virol 2007; 81:8180–8191.
13. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Kedl RM, Mattapallil JJ, et al. HIV Gag protein conjugated to a toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A 2005; 102:15190–15194.
14. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Miles AP, Saul A, et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 2006; 203:1249–1258.
15. Schlaepfer E, Audige A, Joller H, Speck RF. TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. J Immunol 2006; 176:2888–2895.
16. Schlaepfer E, Speck RF. Anti-HIV activity mediated by natural killer and CD8+ cells after toll-like receptor 7/8 triggering. PLoS ONE 2008; 3:e1999.
17. Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science 1989; 244:575–577.
18. Bednarik DP, Mosca JD, Raj NB, Pitha PM. Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated alpha 2-interferon. Proc Natl Acad Sci U S A 1989; 86:4958–4962.
19. Gendelman HE, Baca LM, Turpin J, Kalter DC, Hansen B, Orenstein JM, et al. Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction. J Immunol 1990; 145:2669–2676.
20. Vieillard V, Jouveshomme S, Leflour N, Jean-Pierre E, Debre P, De Maeyer E, et al. Transfer of human CD4(+) T lymphocytes producing beta interferon in Hu-PBL-SCID mice controls human immunodeficiency virus infection. J Virol 1999; 73:10281–10288.
21. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451:425–430.
22. Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, et al. Alpha interferon potently enhances the antihuman immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 2006; 80:7645–7657.
23. Wang FX, Huang J, Zhang H, Ma X. APOBEC3G upregulation by alpha interferon restricts human immunodeficiency virus type 1 infection in human peripheral plasmacytoid dendritic cells. J Gen Virol 2008; 89:722–730.
24. Soumelis V, Scott I, Gheyas F, Bouhour D, Cozon G, Cotte L, et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001; 98:906–912.
25. Lane HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA, Herpin B, et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med 1990; 112:805–811.
26. Hosmalin A, Lebon P. Type I interferon production in HIV-infected patients. J Leukoc Biol 2006; 80:984–993.
27. Bafica A, Scanga CA, Schito M, Chaussabel D, Sher A. Influence of coinfecting pathogens on HIV expression: evidence for a role of toll-like receptors. J Immunol 2004; 172:7229–7234.
28. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365–1371.
29. Equils O, Schito ML, Karahashi H, Madak Z, Yarali A, Michelsen KS, et al. Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication. J Immunol 2003; 170:5159–5164.
30. Equils O, Faure E, Thomas L, Bulut Y, Trushin S, Arditi M. Bacterial lipopoly-saccharide activates HIV long terminal repeat through Toll-like receptor 4. J Immunol 2001; 166:2342–2347.
31. Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res 2000; 28:663–668.
32. Alter G, Suscovich TJ, Teigen N, Meier A, Streeck H, Brander C, et al. Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J Immunol 2007; 178:7658–7666.
33. Meier A, Altfeld M. Toll-like receptor signaling in HIV-1 infection: a potential target for therapy? Expert Rev Anti Infect Ther 2007; 5:323–326.
34. Baenziger S, Heikenwalder M, Johansen P, Schlaepfer E, Hofer U, Miller RC, et al. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 2008 [Epub ahead of print].
35. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434:772–777.
36. Honda K, Yanai H, Mizutani T, Negishi H, Shimada N, Suzuki N, et al. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci U S A 2004; 101:15416–15421.
37. Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev 2008; 19:3–19.
38. Kawai T, Akira S. Antiviral signaling through pattern recognition receptors. J Biochem 2007; 141:137–145.
39. Wang JP, Liu P, Latz E, Golenbock DT, Finberg RW, Libraty DH. Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. J Immunol 2006; 177:7114–7121.
40. Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, Ling EY, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39:523–528.
41. Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, Oh NR, et al. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci U S A 2006; 103:177–182.
42. Schröder NWJ, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005; 5:156–164.
43. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856–1862.
44. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998; 279:389–393.
45. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429–434.
46. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, Hayes E, et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med 2003; 9:928–935.
47. Speelmon EC, Livingston-Rosanoff D, Li SS, Vu Q, Bui J, Geraghty DE, et al. Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol 2006; 80:2463–2471.
48. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, et al. HLA alleles associated with delayed progression to aids contribute strongly to the initial CD8(+) T cell response against HIV-1. PLoS Med 2006; 3:e403.
49. Bochud PY, Hersberger M, Taffe P, Bochud M, Stein CM, Rodrigues SD, et al. Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 2007; 21:441–446.
50. Oh DY, Taube S, Hamouda O, Kücherer C, Poggensee G, Jessen H, et al. A frequent functional toll-like receptor 8 variant is associated with restriction of HIV disease restriction. J Infect Dis 2008; 198:701–709.
51. Schott E, Witt H, Neumann K, Taube S, Oh DY, Schreier E, et al. A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol 2007; 47:203–211.
52. Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, Walter H, et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 2001; 26:266–273.
53. Neifer S, Somogyi S, Schlote F, Berg T, Poggensee G, Kuecherer C. Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment. AIDS 2006; 20:2231–2233.
54. Poggensee G, Kucherer C, Werning J, Somogyi S, Bieniek B, Dupke S, et al. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med 2007; 8:511–519.
55. Hendel H, Henon N, Lebuanec H, Lachgar A, Poncelet H, Caillat-Zucman S, et al. Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:381–386.
56. Misrahi M, Teglas JP, N'Go N, Burgard M, Mayaux MJ, Rouzioux C, et al, French Pediatric HIV Infection Study Group. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. JAMA 1998; 279:277–280.
57. Ioannidis JP, Contopoulos-Ioannidis DG, Rosenberg PS, Goedert JJ, De Rossi A, Espanol T, et al. Effects of CCR5-delta32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis. AIDS 2003; 17:1631–1638.
58. Mulherin SA, O'Brien TR, Ioannidis JP, Goedert JJ, Buchbinder SP, Coutinho RA, et al. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS 2003; 17:377–387.
59. Pasi KJ, Sabin CA, Jenkins PV, Devereux HL, Ononye C, Lee CA. The effects of the 32-b CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia. Br J Haematol 2000; 111:136–142.
60. Oh DY, Jessen H, Kucherer C, Neumann K, Oh N, Poggensee G, et al. CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individual. PLoS ONE 2008; 3:e2747.
61. Patke DS, Langan SJ, Carruth LM, Keating SM, Sabundayo BP, Margolick JB, et al. Association of Gag-specific T lymphocyte responses during the early phase of human immunodeficiency virus type 1 infection and lower virus load set point. J Infect Dis 2002; 186:1177–1180.
62. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9:65–71.
63. Treatment guidelines updated. AIDS Patient Care. STDS 2008; 22:85–88.
64. Zhou S, Kurt-Jones EA, Fitzgerald KA, Wang JP, Cerny AM, Chan M, et al. Role of MyD88 in route-dependent susceptibility to vesicular stomatitis virus infection. J Immunol 2007; 178:5173–5181.
65. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci U S A 2004; 101:3516–3521.
66. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005; 79:7269–7272.
67. Berghofer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H. TLR7 ligands induce higher IFN-alpha production in females. J Immunol 2006; 177:2088–2096.
68. Schott E, Witt H, Neumann K, Bergk A, Halangk J, Weich V, et al. Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy. J Viral Hepat 2008; 15:71–78.
69. Hegde RS, Bernstein HD. The surprising complexity of signal sequences. Trends Biochem Sci 2006; 31:563–571.
70. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000; 97:2709–2714.
71. Walker BD. Elite control of HIV infection: implications for vaccines and treatment. Top HIV Med 2007; 15:134–136.
This article has been cited 6 time(s).
International Reviews of ImmunologyThe Genetics of Innate Immunity Sensors and Human DiseaseInternational Reviews of Immunology
Journal of Gastroenterology and HepatologyToll-like receptors in hepatitis C infection: Implications for pathogenesis and treatmentJournal of Gastroenterology and Hepatology
Biomed Research InternationalIncreased Toll-Like Receptor Signaling Pathways Characterize CD8+Cells in Rapidly Progressive SIV InfectionBiomed Research International
Journal of VirologyToll-Like Receptor 7 Inhibits Early Acute Retroviral Infection through Rapid Lymphocyte ResponsesJournal of Virology
Journal of Interferon and Cytokine ResearchToll-Like Receptor Polymorphisms, Inflammatory and Infectious Diseases, Allergies, and CancerJournal of Interferon and Cytokine Research
Analytical LettersQuadruplex Genotyping of Tlr-8 Polymorphisms in A Single ReactionAnalytical Letters
cytokines; disease susceptibility; genetics; HIV; innate immunity; single nucleotide polymorphism; toll-like receptors
© 2009 Lippincott Williams & Wilkins, Inc.
Highlight selected keywords in the article text.